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ABSTRACT
The aureolic acid antibiotic mithramycin (MTM) binds
selectively to GC-rich DNA sequences and blocks
preferentially binding of proteins, like Sp1 transcrip-
tion factors, to GC-rich elements in gene promoters.
Genetic approaches can be applied to alter the MTM
biosynthetic pathway in the producing microorgan-
ism and obtain new products with improved pharma-
cologicalproperties.Here,wereportonanewanalog,
MTM SDK, obtained by targeted gene inactivation of
the ketoreductase MtmW catalyzing the last step in
MTM biosynthesis. SDK exhibited greater activity as
transcriptionalinhibitorcomparedtoMTM.SDKwasa
potent inhibitor of Sp1-dependent reporter activity
and interfered minimally with reporters of other
transcription factors, indicating that it retained a
high degree of selectivity toward GC-rich DNA-
binding transcription factors. RT–PCR and
microarray analysis showed that SDK repressed
transcription of multiple genes implicated in critical
aspects of cancer development and progression,
including cell cycle, apoptosis, migration, invasion
and angiogenesis, consistent with the pleiotropic
roleofSp1family transcriptionfactors.SDKinhibited
proliferation andwasapotentinducerofapoptosisin
ovarian cancer cells while it had minimal effects on
viabilityof normal cells.The new MTM derivativeSDK
couldbeaneffectiveagentfortreatmentofcancerand
otherdiseaseswithabnormalexpressionoractivityof
GC-rich DNA-binding transcription factors.
INTRODUCTION
Deregulation of transcription factor activity is an important
event in the pathogenesis of many human diseases, including
cancer, chronic inﬂammatory, cardiovascular and neurode-
generative disorders (1,2). Compounds able to block over-
active transcription factors and modulate gene expression
could be very attractive therapeutic agents. Aureolic acid
antibiotics, like mithramycin (MTM) and chromomycin,
are natural polycyclic aromatic polyketides produced by
various Streptomyces species (3). These compounds contain
an identical tricyclic chromophore with a unique hydrophilic
side chain attached in 3-position and different saccharide
chains attached in 2 and 6 positions (3). Compounds like
MTM have the interesting property of binding to GC-rich
DNA sequences selectively (4). Mg
2+-coordinated dimers of
MTM bind non-covalently to DNA in the minor groove with
the chromophores parallel to the sugar-phosphate backbone
and saccharide chains wrapping across the minor groove
(4,5). The chromophores form speciﬁc hydrogen bonds
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doi:10.1093/nar/gkl063with the NH2 of guanines determining the selectivity for
GC-rich sequences (4,5). As consequence of this sequence
selectivity, MTM blocks preferentially binding of proteins,
like Sp1 family transcription factors, to GC-rich sequences in
gene promoters and inhibit transcription of genes regulated
by these factors (6–10). In this manner, MTM has the poten-
tial to inhibit expression of many genes involved in cancer
pathogenesis and therapeutically relevant (6–11). MTM is
active against a variety of human cancers in experimental
models and has been used clinically for many years to treat
testicular carcinoma as well as hypercalcemia in patients with
metastatic bone lesions and Paget’s disease (3,12,13). Its
current clinical use is limited by its severe side effects
that include gastrointestinal, hepatic, kidney and bone mar-
row toxicity. Nevertheless, MTM has recently attracted
renewed attention as an experimental therapeutic agent
in cancer and non-cancer-related disorders (14–22). The
availability of new analogs with improved pharmacological
and toxicological properties and a better understanding of
their effects on gene expression may open new perspectives
for therapeutic use of this class of compounds.
Metabolic engineering, in which a compound’s biosyn-
thetic pathway is altered by gene inactivation, recombination
or mutation, has been used successfully to increase biodiver-
sity and produce new ‘unnatural’ natural products with an
improved pharmacological proﬁle (23,24). The MTM biosyn-
thetic pathway has been almost completely elucidated in
recent years (25–31). Its biosynthesis proceeds through the
condensation of multiple acyl-coA monomers catalyzed by
type II polyketide synthases. The initial condensation phase
leads to the formation of the tetracyclic intermediate
premithramycinone, which is subsequently modiﬁed by the
addition of saccharide chains leading to the formation of
premithramycin B (Figure 1). The ﬁnal steps, which are
catalyzed by the oxygenase MtmOIV and ketoreductase
MtmW, are the oxidative cleavage of the fourth ring of
premithramycin B followed by the decarboxylation and
ketoreduction of the pentyl side chain in C-3 (25,29). We
have applied genetic approaches to modify MTM biosynthe-
sis in the attempt to produce compounds that would share the
same basic mechanism of action of the parent compound, but
have increased potency and/or improved therapeutic index.
Attempts made over the years have yielded compounds
exhibiting distinct structural changes and have allowed us
to gain information on the structure-activity relationships
of this type of compounds (11,28–30). While modiﬁcations
of the carbohydrate and aglycon moieties disrupted almost
completely activity, changes in the 3-side chain were more
promising (11,28,29).
In an effort to ﬁnd new analogs with improved pharmaco-
logical properties, we have identiﬁed recently a new
compound produced by targeted inactivation of the
ketoreductase MtmW gene. The compound, named MTM
SDK (SDK), had a fully glycosylated tricyclic aglycon and
differed with respect to MTM only in the structure and length
of the 3-side chain (Figure 1). Here, we show that SDK is a
potent inhibitor of transcription, cancer cell proliferation and
survival. Our data suggest that this new MTM analog could be
a valid agent for treatment of cancer and other diseases with
abnormal activity of GC-rich DNA-binding transcription
factors and over-expression of their target genes.
MATERIALS AND METHODS
Isolation of SDK and SK
MTM and the secondary metabolite MTM SK (SK) (Figure 1)
were initially isolated as described previously (29). The fol-
lowing procedure was later adopted to produce large amounts
of SDK and SK. Seed cultures were ﬁrst prepared by inocu-
lating spores of Streptomyces argillaceus M7W1 in TSB (tryp-
tone soya broth) medium and incubating in an orbital shaker at
30 C for 36 h (29). Seed cultures (3.5 ml/ﬂask) were then used
to inoculate 10 Erlenmeyer ﬂasks with 100 ml of modiﬁed R5
medium. After three days, cultures were monitored by high-
performance liquid chromatography (HPLC) to avoid decom-
position of SDK into another secondary metabolite, MTM SA
(29). The cultures were harvested as soon as SA was observed
(Supplementary Data S1). Cells were centrifuged at
4000 r.p.m. (750 mL EC 2273 rotor; 4550 g) for 35 min,
and the culture ﬁltrate was passed through a 5 · 10 cm RP
C18 column using vacuum (diaphragm pump, 1–5 mbar). The
column was washed with 100% water and then eluted with a
5–30% acetonitrile gradient in water. Only fractions
containing SK and SDK were collected. These fractions
were combined and further puriﬁed on a 2 · 10 cm RP
C18 column using a gradient of acetonitrile from 25 to
30% in water. SK was eluted ﬁrst (yield  50 mg), followed
by SDK (yield  30 mg). NMR spectroscopy and mass
spectrometry data of SDK are presented as Supplementary
Data S2. Stock solutions of MTM, SK and SDK were prepared
in sterile DMSO at a concentration of 10 mM and stored at
 20 C. For each experiment drug dilutions at the desired
concentrations were made in tissue culture medium and
used immediately.
Cell lines and plasmids
A2780, OVCAR3, OVCAR5, OVCAR8, OVCAR432,
SKOV3 and IGROV1 ovarian cancer cell lines were main-
tained in RPMI 1640 supplemented with 10% heat-inactivated
fetal bovine serum (FBS). Primary cultures of normal human
ﬁbroblasts were maintained in DMEM supplemented with
10% heat-inactivated FBS. Luciferase reporter plasmids
with the c-src, c-myc and ets2 promoters have been described
previously (11,32,33). The TransLucent Sp1 reporter
(Sp1-Luc) and control reporter (Control-Luc) vectors were
purchased from Panomics (Redwood City, CA). The
pCMV-Sp1 and PPREx3-tk-Luc were gifts of Dr D. Kardassis
and Dr R. Evans, respectively. The AP1, SRE and NF-kB
reporters were provided by Dr G. Natoli.
Luciferase reporter assays
Cells were plated at a density of 2 · 10
4 cells/well in 48-well
plates and transfected with 200 ng of reporter plasmid using
Lipofectamine2000 (Invitrogen). After 4 h, the medium was
removed and replaced with fresh medium containing the
desired concentrations of each compound. Cells were incu-
bated for additional 18 h and luciferase activity was measured
in cell extracts using the Promega Luciferase assay system.
Reporter activity was normalized to protein content in cell
extracts measured with the BioRad assay.
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Figure 1. Biosynthesis of the MTM analogs SDK and SK. (A) The oxygenase MtmOIV and ketoreductase MtmW catalyze the conversion of premithramycin B to
mithramycin(MTM).InactivationofMtmWpreventssynthesisofMTMandresultsinaccumulationoftheintermediateproductDK,whichisthenconvertedintoSK
andSDK.RegionsofrelevantMTM-DNAinteractionareindicated.(B)SidechainrearrangementsleadingtoformationofSKandSDKfromtheMtmOIVproductDK.
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Fluorescence spectroscopy experiments were carried at 20 C
in 20 mM Tris–HCl buffer, pH 8.0. Drugs were pre-incubated
in the same buffer containing 10 mM MgCl2 for 1 h at room
temperature to ensure complete drug–Mg
2+ complex forma-
tion.SalmonspermDNA was pre-incubated inthe samebuffer
containing 10 mM MgCl2 to avoid cation-induced changes in
conformation during its association with the drug. DNA was
added in small aliquots to the samples before taking ﬂuores-
cence measurements. DNA concentration during the titration
experiments ranged from 0 to 200 mM while total drug con-
centration was essentially kept constant at 20 mM. Fluores-
cence emission spectra were collected between 500 and
640 nm upon excitation at 470 nm (bandwidths of 5 and
10 nm for the excitation and emission, respectively) using a
PerkinElmer LS55 Luminescencespectrometer equipped with
a 100 ml quartz cuvette. A total of six scans per experiment
were recorded and the error in the ﬂuorescence intensity
between measurements was <5%. The change in ﬂuorescence
emissionintensity(DF;lex¼470nmandlemi¼515nm) after
each addition of DNA and its maximum value (DFmax) were
calculated for each titration experiment. Dissociation con-
stants of the drug–DNA complexes were determined by
means of non-linear curve ﬁtting analysis of ﬂuorescence titra-
tion data from three independent experiments. DNase I foot-
printing experiments were done on a 223 bp c-src promoter
fragment as described previously (11). Samples were analyzed
by electrophoresis on denaturating polyacrylamide gels.
Electrophoretic mobility shift assays
Nuclear extracts were prepared using NE-PER
R Nuclear and
Cytoplasmic extraction kit (Pierce Biotechnology) according
to manufacturer’s instructions. Protein concentration in
nuclear extracts was determined using the BCA protein
assay kit (Pierce Biotechnology). HPLC-puriﬁed single-
stranded oligonucleotide containing a canonical Sp1 binding
sequence (50-ATTCGATCGGGGCGGGGCGAGC-30) and
the complementary oligonucleotide were purchased from
Sigma Genosys (Steinheim, Germany). Both oligonucleotides
were labeled by adding biotinylated ribonucleotides at the
30-OH end using the Biotin 30 end DNA labeling kit (Pierce
Biotechnology). Duplex DNA was formed by incubating the
labeled oligonucleotides in 10 mM Tris–HCl, pH 8.0, 50 mM
NaCl, 1 mM EDTA and 10 mM MgCl2 for 15 min at 95 C
followed by slow cooling to room temperature. Duplex DNA
(50–75 fmol) was then incubated with the compounds in a
buffer containing 10 mM Tris–HCl, pH 7.5 and 5 mM MgCl2
for 1 h at 20 C. Nuclear extract was pre-incubated on ice in
binding buffer containing 10 mM Tris–HCl, pH 7.5, 50 mM
KCl, 1 mM DTT, 2.5% glycerol, 2.5 mM MgCl2,2 5n g
Poly(dI–dC), 0.5 mM EDTA and 0.05% NP-40. Aliquots of
nuclear extract (6 mg of protein/sample) were combined with
drug–DNA complexes and incubated for additional 20 min at
20 C. Gel mobility shift assays were performed using the
LightShift Chemiluminescent EMSA kit (Pierce Biotechnol-
ogy) following the manufacturer’s instructions. Non-
denaturing 6% polyacrylamide gels were pre-run for 1.5 h
at 4 C and electrophoresis was carried out at 150 V for
45 min using 0.5· TBE as running buffer. Gels were trans-
ferred to positive-charged Biodyne
R B Nylon membranes
(Pierce Biotechnology) and cross-linked in BioRad GS
Gene Linker. Detection of biotin-labeled DNA was done
using Streptavidin–horseradish peroxidase conjugate and
Chemilumiscent Substrate (Pierce Biotechnology).
Cellular uptake
A2780 cells were incubated with 100 mM of each compound
for 2 or 4 h. At the end of the drug incubation, cells were
washed with ice-cold phosphate-buffered saline (PBS) repeat-
edly, harvested and immediately analyzed by ﬂow cytometry.
To isolateintactnuclei,cells weresuspendedinice-coldnuclei
extraction buffer (320 mM sucrose, 5 mM MgCl2,1 0m M
HEPES and 1% Triton X-100 at pH 7.4) and incubated for
10 min on ice. Nuclei were recovered by centrifugation,
washed twice and then analyzed by ﬂow cytometry. Nuclei
yield and integrity were conﬁrmed by trypan blue staining and
microscopic examination.
RNA isolation, RT–PCR and real-time PCR
Cells were seeded at a density of 1 · 10
5 cells/ﬂask and treated
with drugs for the indicated times. Total RNA was isolated
using Trizol (Invitrogen) and further puriﬁed with RNeasy
MiniKit (Qiagen). RNA concentration was determined
using a NanoDrop spectrophotometer (Witec AG, CH).
RT–PCR was performed under non-saturating conditions
using the SuperScript One-Step RT–PCR system (Invitrogen)
and gene-speciﬁc primers (for primer sequences and PCR
conditions see Supplementary Data S3). PCR products were
separated on 2% agarose gels, stained with ethidium bromide
and visualized using the AlphaImager 3400 (AlphaInnotech).
Band intensity was determined using the AlphaEase Software.
For quantitative real-time PCR, 1 mg of total RNA was
reverse-transcribed using SuperScript First-Strand Synthesis
System (Invitrogen). Real-time PCR was performed in tripli-
cate samples on an ABI Prism 7000 Sequence Analyzer using
primer sets for VEGF and b-2-microglobulin (Assays-
on-Demand, ABI) and TaqMan Universal PCR Mastermix
(ABI). Standard curves were generated for each primer set
and b-2-microglobulin RNA was used as control to quantify
VEGF RNA.
Immunoblotting
Cell lysates were prepared from control and drug-treated cells
and proteins separated on SDS–polyacrylamide gels as
described (32). Blots were incubated with an antibody able
to detect the cleaved 85 kDa form of PARP (BD Pharmingen),
while an antibody against a-tubulin (Santa Cruz) was used to
control sample loading. Sp1 protein level was determined
using an anti-Sp1 antibody (clone sc59, SantaCruz). Blots
were developed using peroxidase-conjugated secondary anti-
bodies and the enhanced chemiluminescence system (ECL,
Amersham).
Microarray analysis
Cells were plated in tissue culture ﬂasks and incubated without
or with 100 nM SDK for 6 h. Three independent replicates
were done for each experimental group. Total RNA was iso-
lated usingTrizol andRNeasycolumns (Qiagen). RNA quality
was veriﬁed using the 2100 BioAnalyzer (Agilent Technolo-
gies). Of total RNA 10 mg was labeled and hybridized to
1724 Nucleic Acids Research, 2006, Vol. 34, No. 6HG-U133A and B Affymetrix GeneChips according to the
manufacturer’s protocol. After overnight incubation, the
arrays were washed on the Fluidics Station 400 and images
collected on GeneChip Scanner 3000 using the GeneChip
Operating System (GCOS) software. Raw signals were
extracted with MAS 5.0 software (Affymetrix) and further
analysis was performed using the Bioconductor statistical
package (www.bioconductor.org). Expression values were
calculated from the raw CEL ﬁles using RMA (34). To remove
non-varying genes, a variational ﬁlter was applied to the data
to retain genes with a SD of at least 0.2 across all samples.
Transcripts with statistically signiﬁcant changes in expression
between the two treatment groups were identiﬁed from this set
usingSAM (35).A cut-off value of D ¼ 0.5was used giving an
estimated FDR of 0.027 and q-values for individual transcripts
smaller than 0.031. Approximately 3400 transcripts were
found to be differentially expressed with most transcripts
(n ¼ 3355) down-regulated and only 49 transcripts
up-regulated. A large number of transcripts ( 2400) were
reduced <2-fold, while  900 transcripts had a >2-fold change
in expression. Only genes (n ¼ 460) with >2.5-fold change
in expression were considered for further analysis and func-
tional classiﬁcation (Supplementary Data S2). The Panther
Classiﬁcation System was used to classify affected genes in
biological process, molecular function and pathway classes
(36). Presence of GC-rich sequence and Sp1-binding sites
in gene promoters was searched using GeneSpring 7.2
software (Silicon Genetics), DBTSS (http://dbtss.hgc.jp/
index.html) or AliBaba 2.1 (http://darwin.nmsu.edu).
Cell proliferation, cell cycle and apoptosis assays
Cells were seeded in 96-well plates at a density of 1.5–2 · 10
3
cells/well and incubated with drugs for 72 h. Each treatment
was performed in triplicate and experiments were repeated at
least three times. The number of viable cells at the end of the
drug incubation was determined using a colorimetric MTT
assay (37). For cell cycle analysis, cells (1 · 10
5cells/ﬂask)
were treated for 24 or 48 h and then harvested, washed with
PBS, and ﬁxed in 80% ETOH. After staining with propidium
iodide, samples were analyzed by ﬂow cytometry (FACSCal-
ibur, Becton Dickinson) as described previously (37). Cell
cycle distribution and percentage of apoptoticcellswere deter-
mined using ModFit (Verity). For detection of apoptotic cells,
control and drug-treated cells were harvested, washed with
PBS, and incubated with Annexin V-FITC and propidium
iodide before analysis by ﬂow cytometry.
RESULTS
Biosynthesis of SDK
The last steps in MTM biosynthesis are catalyzed by the
oxygenase MtmOIV and ketoreductase MtmW (25,29). Modi-
ﬁcations of the isolation procedure of MTM metabolites from
the S.argillaceus M7W1 mutant strain showed that targeted
inactivation of the MtmW gene resulted in the accumulation of
a new product, SDK, in addition to the previously described
SK (Figure 1A). Detection of SDK, which is acid sensitive and
poorly soluble in ethylacetate, had been missed in earlier
work because an ethylacetate extraction step and HPLC acidic
elution solvent were used in the isolation procedure (29). The
newly discovered analog SDK (for short side chain, diketo)
had the fully glycosylated tricyclic aglycon and 3-butyl side
chain similar to SK, but with two keto groups instead the keto-
and secondary alcohol group of SK. Figure 1B shows the
proposed pathway leading to the formation of SK and SDK
via a rearrangement process triggered by the inactivation of
MtmW. This mechanism is supported by
13C incorporation
studies, which proved that C-30 is excised during the formation
of SK (29). In the absence of the ketoreductase, the product of
the MtmOIV reaction, MTM DK (DK), undergoes a sponta-
neous rearrangement in its 3-b-diketo side chain, triggered by
a b-shift and followed by elimination of either formic acid or
formaldehyde to form SK and SDK, respectively. This view
has been conﬁrmed recently through studies with the isolated
enzyme MtmOIV, showing that SDK is a major end product of
the conversion of premithramycin B at pH 8.25 (38). A similar
compound with a short a-diketo-butyl side chain was also
found as a product of a mutant of the chromomycin producer
Streptomyces griseus ssp. Griseus (39).
Transcription inhibition by MTM analogs
We used a luciferase reporter assay to compare the ability of
MTM derivatives to block transcription driven by GC-rich
DNA-binding transcription factors, like Sp1. Transfection
of A2780 cells with the Sp1 reporter gave high levels of
activity with >30-fold induction compared with the control
vector lacking Sp1-binding sites, consistent with the high Sp1
proteinlevelseeninwesternblots(datanotshown).Next,cells
were transfected with the Sp1 reporter and incubated with
100 nM of each MTM derivative for 18 h before measuring
luciferase activity. The new analog SDK was the most potent
compound in the reporter assays inducing >90% inhibition at
100 nM, to a level comparable with that seen with the control
vector lacking Sp1 binding sites (Figure 2A). At this dose,
MTM and SK inhibited the Sp1 reporter only 40 and 60%,
respectively. All other MTM derivatives were inactive at this
dose. SDK was active also at lower concentrations with  60
and 90% inhibition at 25 and 50 nM, respectively (Figure 2B).
Transfection of increasing amounts of a Sp1 expression vector
prior to SDK treatment prevented inhibition of the reporter
completely at 25 nM and partially at 50 nM, conﬁrming that
the compound acted by competing with Sp1 for binding to
GC-rich consensus sequence (Figure 2B). Next, we extended
the analysis to promoter reporters of genes, like c-myc, ets2
and c-src, containing GC-rich elements and Sp1-binding sites.
Activity of these reporters was inhibited by SDK with 80–90%
inhibition at 50 nM (Figure 2C). On the other hand, reporter
constructs containing responsive elements for other transcrip-
tion factors (i.e. AP1, SRE, PPRE and NF-kB) without
GC-rich elements were not or much less affected by SDK
compared with the Sp1 reporter (Figure 2D).
DNA-binding properties and cellular uptake
of MTM analogs
To determine the factors that might be responsible for the
increased potency of the new analog, we compared DNA-
binding properties, ability to block Sp1 binding and cellular
uptake of MTM, SK and SDK. DNA-binding properties of
the three compounds were studied by monitoring changes in
Nucleic Acids Research, 2006, Vol. 34, No. 6 1725ﬂuorescence emission spectra at increasing DNA concentra-
tions. Binding to DNA induces dequenching of the drug’s
ﬂuorochromes with an increase in ﬂuorescence intensity.
Figure 3A shows the changes of ﬂuorescence intensity nor-
malized to the maximum ﬂuorescence intensity (DF/DFmax)
for each compound as a function of the DNA concentration in
the binding reactions. SDK and MTM bound to DNA with
similar afﬁnity, while SK had lower afﬁnity. Dissociation
constants (Kd) calculated from the ﬂuorescence titration
experiments were 19, 20 and 40 mM for MTM, SDK and
SK, respectively. Footprinting experiments done on a 223
bp fragment of the c-src promoter (11) conﬁrmed that SDK
had similar preference for GC-rich sequences as MTM and SK
(data not shown).
Next, we examined the ability of the compounds to interfere
with GC-rich DNA-binding proteins, like Sp1, in gel mobility
shift assays. A duplex oligonucleotide probe containing a
canonical Sp1-binding sequence was incubated with the com-
pounds before the addition of nuclear extract. Presence of Sp1
and binding to the probe had been demonstrated in separate
experiments by Western blotting and competition assays (data
notshown).SDK at10mMinhibited almostcompletely forma-
tion of the Sp1–DNA complex (Figure 3B). MTM was less
effective in blocking Sp1 binding despite the similar binding
afﬁnity shown in ﬂuorescence titration experiments. SK, con-
sistent with its reduced binding to DNA, was less effective
than both MTM and SDK in blocking Sp1 binding.
The ability to inhibit transcription in cells could be greatly
affected by differences in cellular uptake. Therefore, ﬂow
cytometry analysis was carried out to measure drug accumu-
lation following incubation of cells with the compounds. SDK
was taken up by cells very rapidly and accumulated in much
larger amounts than MTM (Figure 3C). In addition to enter
cells rapidly, SDK accumulated in cell nuclei as shown by
ﬂuorescence microscopy and ﬂow cytometry of isolated nuclei
(data not shown). The amount of SK entering cells was also
higher than MTM, a fact that could compensate at least in part
for its reduced DNA-binding properties.
Effects of MTM analogs on endogenous gene
transcription
To assess the effects on transcription of endogenous genes,
A2780 cells were incubated with MTM, SK and SDK for 24 h
and expression of genes, like c-myc, c-src, hTERT, VEGF and
bcl-xL, with known Sp1-binding sites was monitored by
RT–PCR. All three compounds inhibited transcription,
although there were clear differences in their relative potency
(Figure 4A). SDK inhibited transcription of all the genes by at
least 90% at 50 nM. SK was less potent than SDK, reaching
comparable levels of inhibition at 100 nM. MTM reduced c-
myc, c-src and hTERT transcript levels by 50–70% at 100 nM,
whileit inhibited bcl-xLandVEGF <50%.Thus, bothSDKand
SK inhibited transcription at lower concentrations and to a
higher degree than MTM.
The kinetics of SDK-induced transcription inhibition was
determined by measuring c-myc and VEGF RNA levels at
different times from the start of the treatment. Reduction of
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Figure 2. EffectsofMTManalogsonpromoterreporteractivity.(A)A2780cellsweretransfectedwithSp1reportervectorfor4handincubatedfor18hinmedium
with or without 100 nM of the indicated compounds before measuring luciferase activity. Data are mean ± SD of triplicate samples. *P < 0.01 as compared with
control cells. MTM, mithramycin; SDK, mithramycin SDK; SK, mithramycin SK; 4E-K, 4E-keto-mithramycin; PreB, premithramycin B; 7DM,
7-demethylmithramycin; 4C-K, 4C-keto-demycarosylmithramycin. (B) Sp1reporter activity in A2780cells transfected with increasing amountsof Sp1 expression
vector or empty vector and treated with 25 and 50 nM of SDK. *P < 0.01and **P < 0.001 compared with control cells. (C) Luciferase activity in A2780 cells
transfected with c-myc, ets2 and c-src promoter reporters and treated with 50 nM of SDK. *P < 0.01 compared with control cells. (D) Luciferase activity in cells
transfected with PPRE, AP1, NF-kB and SRE reporters and treated with 50 nM of SDK.
1726 Nucleic Acids Research, 2006, Vol. 34, No. 6c-myc RNA to <20% of control was seen within 6 h of
treatment with SDK (Figure 4B). At this time, MTM induced
only marginal effects on c-myc RNA, while a more consistent
decrease was seen only after 24 h. A similar kinetics of
inhibition was observed measuring VEGF RNA by real-time
RT–PCR with >80% reduction in transcript levels within 6 h
of treatment with SDK (Figure 4B, lower panel). We assessed
also the reversibility of the SDK effects on transcription. Both
c-myc and VEGF RNA levels were reduced >80% after 6 h
with 50 nM of SDK (Figure 4C). Following drug removal,
transcription of both genes was slowly restored over time.
RNA levels were  50% of the control levels at 24 and
48 h after drug removal, while an almost complete recovery
was seen after 72 h.
Gene expression profiling
GC-rich DNA-binding compounds, like SDK, could affect
transcription of several genes. To better understand the extent
of the transcriptional response induced by SDK and the
mechanism underlying its anti-proliferative and pro-apoptotic
activity, we examined gene expression of control and
drug-treated cells using the HG-U133 Affymetrix GeneChip
set, which contained probes for  45000 transcripts. Approxi-
mately 460 genes were down-regulated >2.5-fold upon
SDK treatment (Supplementary Data S4). Table 1 shows
the top 50 genes with the highest level of down-regulation
(>4-fold). Many of the top down-regulated genes (e.g.
MYC, VEGF, DKK1, MCL1, ID1, ID3 and ZNF217) are
known to be up-regulated in cancer cells and have a deﬁned
role in cancer pathogenesis. Furthermore, most of these
genes have GC-rich elements and Sp1 binding sites in their
regulatory regions.
Functional classiﬁcation of the genes down-regulated by
SDK was done using the Panther Classiﬁcation tool, which
gives also a statistical estimate of the degree of over-
representation of a given functional class. Table 2 shows bio-
logical process, molecular function and pathway classes that
were over-represented among SDK down-regulated genes
with the highest statistical signiﬁcance. SDK affected a con-
siderable number of biological processes highly relevant to
cancer pathogenesis, including developmental processes, cell
cycle control, signal transduction pathways, cell proliferation
and differentiation, oncogenesis and angiogenesis, consistent
with the pleiotropic role of Sp1 family transcription factors.
Analysis of molecular function and biological process classes
indicated a predominance of genes involved in transcription
regulation and nucleic acid metabolism, suggesting that SDK
treatment could affect expression of multiple transcriptional
regulatory and co-regulatory factors. This is likely a secondary
effect due to the presence of GC-regulatory elements and
Sp1-binding sites in the promoter of many of these genes.
Critical cellular pathways, like the Wnt, TGF-b, Hedgehog
and apoptosis signaling pathway, were also over-represented
among the SDK down-regulated genes, although only few
genes could be assigned to the distinct pathways with limited
statistical power.
Notably, a small number of genes (n ¼ 49) were
up-regulated upon treatment with SDK, with few transcripts
having a >2-fold change in expression (Supplementary Data
S5). Among the up-regulated genes were the gene encoding
spermidine/spermine N1-acetyltransferase (SSAT) and the
gene encoding the BCL2-interacting protein BNIP3L. Both
proteins have a pro-apoptotic function.
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Nucleic Acids Research, 2006, Vol. 34, No. 6 1727Effects of MTM analogs on proliferation of human
ovarian cancer cell lines
SDK was an effective inhibitor of transcription of genes criti-
cal to cell growth and survival and thus could represent a
useful cancer therapeutic agent. Therefore, we examined
the effects of MTM, SK and SDK on proliferation of ovarian
cancer cells. Upon a 72 h continuous exposure, all three com-
pounds inhibited growth of ovarian cancer cells at nanomolar
concentrations (Figure 5). SDK was the most potent com-
pound with IC50 up to 2-fold lower than MTM and SK in
the majority of cases (Table 3). Short incubations with
SDK were equally effective in inhibiting cell growth. Incuba-
tion of A2780 cells with 100 nM of SDK for 4 or 6 h followed
by incubation in drug-free medium for up to 72 h produced an
effect identical to the 72 h continuous exposure (i.e. >80%
inhibition), indicating that the drug’s effects were not
reversible upon its removal (data not shown). Thus, even
brief exposures to relatively low doses of SDK-induced
persistent effects on cell growth.
Cell cycle alterations and apoptosis induced
by MTM analogs
SDK inhibited growth of cancer cells, an effect that could be
related to arrest of cell cycle progression and/or induction of
cell death. To examine the processes leading to growth inhibi-
tion, A2780 cellswere treated with the three compounds for24
and 48 h and cell cycle distribution monitored by ﬂow cytome-
try. Cells incubated with 100 nM of MTM for 24 h showed a
decrease of S phase cells (42% versus 32%),indicative of G1/S
phase arrest, while minimal induction of cell death (i.e. cells
with sub-G1 DNA content) was evident at this time
(Figure 6A). Induction of cell death became more evident
only after 48 h of treatment with MTM ( 20% of sub-G1
cells). Unlike MTM, the major effect of SDK in these cells
was induction of cell death. The fraction of cells with sub-G1
DNA content was 38% already at 24 h and increased to  50%
at 48 h (Figure 6A). With respect to the induction of apoptosis,
SKbehavior wasintermediatebetweenthatofSDKandMTM,
with a higher percentage of apoptotic cells than MTM both at
24 and 48 h (10 and 40%, respectively). Induction of cell death
by SDK was conﬁrmed by immunoblotting showing PARP
cleavage, which indicates caspase activation, within 24 h of
treatment with SDK (data not shown). Furthermore, annexin
V-PI staining and ﬂow cytometry showed  50% of apoptotic
cells following 24 h incubation with SDK (Figure 6B, upper
panels). Treatment of cells with SDK for 6 h followed by
incubation in drug-free medium for 18 h resulted in a similar
level of apoptosis as the 24 h continuous treatment (Figure 6C,
lower panels). Overall, the induction of apoptosis appeared as
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1728 Nucleic Acids Research, 2006, Vol. 34, No. 6a major event underlying the anticancer effect of SDK, which
acted at lower concentrations and more rapidly than MTM.
SDK had a profound effect on proliferation and survival of
cancer cells. We wondered whether SDK would have similar
cytotoxic effects in normal cells, like normal human ﬁbrob-
lasts. Annexin V-PI staining showed the absence of cell death
in normal ﬁbroblasts incubated for 24 h with 50 nM SDK
(Figure 6C). The percentage of Annexin V and PI positive
cells was essentially identical in untreated and SDK-treated
NHF, while >50% of A2780 cells were apoptotic under the
same conditions. Thus, the pro-apoptotic activity of SDK in
ovarian cancer cells was not associated with comparable
cytoxicity in normal cells.
DISCUSSION
Polyketides comprise a large family of structurally diverse
natural products that include widely used pharmaceuticals
with potent anticancer, antibacterial and antifungal activity
(23,24). MTM is a polycyclic aromatic polyketide and, like
other compounds of this class, has interesting pharmacological
properties. Clinical use of MTM and similar compounds, how-
ever, is limited at the present by the induction of severe side
effects. The availability of new MTM analogs with an
improved pharmacological and toxicological proﬁle may
open new possibilities for exploiting the unique properties
of this class of compounds for therapeutic applications.
Table 1. SDK down-regulated genes
a
Gene symbol Gene title Fold change Expression level
ZNF217 Zinc finger protein 217 7.6 8.9
NA CDNA FLJ11397 fis, clone HEMBA1000622 6.7 6.6
SPRY2 Sprouty homolog 2 (Drosophila) 6.5 10.9
ADNP Activity-dependent neuroprotector 6.2 9.9
DKK1 Dickkopf homolog 1 (Xenopus laevis) 6.2 11.6
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 6.1 10.6
SPRY1 Sprouty homolog 1, antagonist of FGF signaling (Drosophila) 6.0 11.1
PUM1 Pumilio homolog 1 (Drosophila) 5.8 10
PDE4D Phosphodiesterase 4D, cAMP-specific 5.7 9.6
CTCF CCCTC-binding factor (zinc finger protein) 5.7 9.7
ARID5B AT rich interactive domain 5B (MRF1-like) 5.6 9.5
NA CDNA FLJ11397 fis, clone HEMBA1000622 5.5 8.4
NUP153 Nucleoporin 153kDa 5.4 9.6
DYRK1A Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A 5.4 9.7
RAI17 Retinoic acid induced 17 5.4 10.4
PHLDA1 Pleckstrin homology-like domain, family A, member 1 5.4 8.3
NEDD9 Neural precursor cell expressed, developmentally down-regulated 9 5.2 7.6
MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 5.2 10.7
EIF2AK3 Eukaryotic translation initiation factor 2-alpha kinase 3 5.2 7.6
SPRED2 Sprouty-related, EVH1 domain containing 2 5.1 10.5
TSC22D2 TSC22 domain family 2 5.1 8.2
RNF184 Ring finger protein 184 5.1 8.4
NA Solute carrier family 38, member 2 5.0 11.9
ID3 Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 5.0 12
PPP1R15B Protein phosphatase 1, regulatory (inhibitor) subunit 15B 5.0 10.3
CRSP6 Cofactor required for Sp1 transcriptional activation, subunit 6, 77kDa 4.9 8.7
C19orf7 Chromosome 19 open reading frame 7 4.9 9.4
TGIF TGFB-induced factor (TALE family homeobox) 4.9 9
PUM2 Pumilio homolog 2 (Drosophila) 4.9 9.5
E2F6 E2F transcription factor 6 4.8 9.5
WAC WW domain containing adaptor with coiled-coil 4.8 10
CHD1 Chromodomain helicase DNA binding protein 1 4.7 6.8
SPRY4 Sprouty homolog 4 (Drosophila) 4.7 12
KLF10 Kruppel-like factor 10 4.7 10.6
ARID4B AT rich interactive domain 4B (RBP1- like) 4.7 6.8
KIAA0232 KIAA0232 gene product 4.6 7.9
KIAA0261 KIAA0261 4.6 7.9
ZCCHC8 Zinc finger, CCHC domain containing 8 4.6 8.2
RBM16 RNA-binding motif protein 16 4.5 8.4
ZNF278 Zinc finger protein 278 4.5 8.7
RSBN1 Round spermatid basic protein 1 4.5 7.8
NA CDNA clone IMAGE:5263531, partial cds 4.5 8.9
SLC38A2 Solute carrier family 38, member 2 4.4 11.8
MAT2A Methionine adenosyltransferase II, alpha 4.4 10.8
C20orf158 Chromosome 20 open reading frame 158 4.4 8.5
DDX20 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 4.4 7.8
SERTAD2 SERTA domain containing 2 4.4 9
LOC58486 Transposon-derived Buster1 transposase-like protein gene 4.3 7.9
ZNRF3 Zinc and ring finger 3 4.3 8.6
IFRD1 Interferon-related developmental regulator 1 4.3 7.4
aDifferentiallyexpressedgenesaftertreatmentofovariancancercellswith100nMSDKfor6hwereidentifiedusingSAM.Thetop50geneswiththehighestdegreeof
down-regulation (fold change) are shown. The expression level in control cells is also indicated.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1729The MTM biosynthetic pathway has been fully character-
ized in recent years, making it possible to apply metabolic
engineering methods to produce new analogs (25–31). Using
this approach, we have identiﬁed new compounds, SDK and
SK, which have improved properties compared with MTM.
SDK was discovered after reevaluating the isolation proce-
duresofthe secondary metabolites ofthemutantstrainM7W1,
in which the last step in MTM biosynthesis had been genet-
ically altered. This new compound was a much more potent
inhibitor of transcription than MTM. SDK inhibited the activ-
ity of a Sp1 reporter by >90% at 50 nM while it interfered
minimally with other transcription factors, indicating that the
compound retained a high degree of selectivity for GC-rich
DNA-binding transcription factors, like Sp1. Furthermore,
expression of increasing amounts of Sp1 reduced the effects
of SDK on Sp1 reporter activity, indicating a direct competi-
tion betweenthe drug and the transcription factor. The potency
of SDK as transcriptional inhibitor was conﬁrmed by deter-
mining its effects on endogenous gene expression by RT–PCR
and microarrays. Theability ofSDK tomodulateexpressionof
multiple genes involved in a variety of cellular functions at
relatively low doses is an important feature that could be
exploited for therapeutic applications in cancer and other
diseases.
The modiﬁed 3-side chain apparently confers to SDK
unique properties that result in improved biological activity
compared to MTM. The pentyl side chain attached at C-3 is a
structural element highly conserved among aureolic acid
antibiotics exhibiting anticancer and antibacterial activity
(3). However, unlike the chromophore and saccharide chains,
the role of the 3-side chain is much less characterized. Indeed,
the availability of compounds like SK and SDK can offer
for the ﬁrst time the opportunity to investigate the relevance
of the 3-side chain. The 30-OH and 40-OH groups in the 3-side
chain of MTM form H-bonds with the DNA phosphate back-
bone with the 40-OH serving as H-bond donor and perhaps
stabilize DNA binding (4). Both the 30- and 40-OH groups are
missing or are in different positions in the 3-side chains of
SDK and SK. The 3-side chain of SDK without OH groups can
act only as H-bond acceptor and does not provide any H-bond
donor function. The 3-side chain of SK has both H-bond donor
and acceptor function, but its potential donor group is in a
position where both MTM and SDK have a keto group, a
potential H-bond acceptor. Considering the absence and repo-
sitioning of these functional groups in the 3-side chains of
SDK and SK compared to MTM, one can imagine differences
in the DNA-binding mode of the three compounds. Thus, the
increased activity of SDK could be due to improvements in the
ability to bind DNA and/or interfere with DNA binding
proteins. Fluorescence titration experiments indicated that
SDK andMTMhadsimilar bindingafﬁnity,while footprinting
studies showed that the new analog retained the GC-rich
sequence selectivity of the parent compound. Despite similar
DNA-binding properties, however, SDK had a greater ability
Table 2. Gene Ontology classes differentially affected by SDK as assessed by Panther
a
U133 (REF)
(Number of genes)
SDK down
(Number of genes)
Expected
(Number of genes)
P-value
Biological process
mRNA transcription 1462 92 32.21 2.33E 20
mRNA transcription regulation 1205 80 26.55 6.16E 19
Nucleoside, nucleotide and nucleic acid metabolism 2607 122 57.44 6.12E 17
Developmental processes 1776 62 39.13 1.94E 04
Cell cycle control 354 19 7.8 4.08E 04
MAPKKK cascade 194 13 4.27 4.58E 04
Stress response 164 11 3.61 1.22E 03
Other developmental process 94 8 2.07 1.31E 03
Angiogenesis 31 4 0.68 5.23E 03
Cell proliferation and differentiation 621 24 13.68 6.20E 03
Oncogenesis 499 20 10.99 8.25E 03
Molecular function
Transcription factor 1602 102 35.3 4.04E 23
Nucleic acid binding 2121 90 46.73 5.85E 10
Zinc finger transcription factor 619 38 13.64 1.97E 08
Transcription cofactor 137 16 3.02 1.08E 07
Other transcription factor 341 24 7.51 9.02E 07
Nuclease 220 14 4.85 4.66E 04
KRAB box transcription factor 423 20 9.32 1.35E 03
Chromatin/chromatin-binding protein 106 8 2.34 2.73E 03
Homeobox transcription factor 166 10 3.66 4.26E 03
Other zinc finger transcription factor 100 7 2.2 7.32E 03
Other signaling molecule 154 9 3.39 7.88E 03
HMG box transcription factor 36 4 0.79 8.73E 03
Pathway
Transcription regulation by bZIP transcription factor 42 5 0.93 2.59E 03
Interferon-gamma signaling pathway 32 4 0.71 5.83E 03
Wnt signaling pathway 289 13 6.37 1.30E 02
TGF-beta signaling pathway 105 6 2.31 3.02E 02
Hedgehog signaling pathway 33 3 0.73 3.74E 02
Apoptosis signaling pathway 123 6 2.71 5.69E 02
aPantheranalysiswasdoneonthe460transcriptswith>2.5-folddecreaseinexpressionafterSDKtreatment.Onlyclassesfoundtobeover-representedamongSDK
down-regulated genes and with lowest P-values are shown.
1730 Nucleic Acids Research, 2006, Vol. 34, No. 6to prevent Sp1 binding in gel mobility shift assays, suggesting
that SDK might bind in ways to block more effectively protein
binding to DNA than MTM perhaps as a result of slight
differences in its binding mode. The greater activity of
SDK as transcriptional inhibitor in cells was also related to
improved cellular uptake. In fact, SDK accumulated in cells
more rapidly and to a greater extent than MTM. Thus, the
combination of tight DNA binding, efﬁcient inhibition of
protein binding and rapid accumulation in cells seems at
the basis of the increased potency of SDK compared to
MTM. In addition to bind tightly to DNA in vitro, SDK
accumulated in large amounts in cell nuclei, suggesting that
the new analog might have easier access and bind more efﬁ-
ciently to nuclear and chromatin targets compared with MTM.
Similarly, the large amount of SK taken up by cells could
compensate for the reduced DNA binding in vitro and explain
the greater activity of this compound as transcriptional
inhibitor compared with MTM.
The ability of SDK to inhibit expression of relevant genes at
relatively low concentrations is an important property. To
better characterize the effects of this compound on transcrip-
tion, we compared gene expression of control and drug-treated
cancer cells using microarrays. SDK inhibited expression of
many genes conﬁrming its potent anti-transcriptional activity.
As expected, genes that were actively transcribed and
possessed GC-rich promoter elements appeared to be more
susceptible to drug-induced inhibition. Overall, SDK had a
profound effect on the transcriptional proﬁle and appeared
able to reverse multiple consequences of the deregulated
transcription program intrinsic of cancer cells. Many genes
affected by SDK were involved in various aspects of cancer
development and progression and represent per se interesting
targets for therapeutic intervention. In addition to genes
involved in cell cycle, cell proliferation and survival, SDK
inhibited expression of genes implicated in cell migration,
invasion and angiogenesis. Thus, the compound might under-
mine the ability of cancer cells to invade tissues, migrate,
produce metastasis and stimulate angiogenesis, in addition
to exert a direct effect on cancer cell proliferation. By inhibit-
ing expression of anti-apoptotic and drug resistance genes,
SDK might also be able to modulate the sensitivity of cancer
cells to chemo- and radio-therapy as proposed recently for
MTM (21,22).
The main targets of GC-rich DNA-binding drugs, like SDK,
are likelytobetranscription factorsofthe Sp1familyand most
of the effects of this compound on cell proliferation and sur-
vival are probably mediated, directly or indirectly, by inter-
ference with the activity of these transcription factors. Sp1 is
the prototype of the family and was the ﬁrst transcription
factor to be puriﬁed, cloned and characterized in mammalian
cells (40). Sp1 is a ubiquitous factor controlling expression of
several cellular genes (40,41). Recent evidence implicates Sp1
in control of cell growth, survival and differentiation and point
to its involvement in cancer pathogenesis (40,42). Over-
expression of Sp1 has been observed in cancers, including
pancreatic, breast, gastric and thyroid cancers, and is a nega-
tive prognostic factor (43–46). Sp1 binding and transcriptional
activity can increase also as result of post-translational
modiﬁcations or altered interactions with oncogenic or
tumor suppressor proteins (40). Increased transcription of
certain cancer-related genes has been found recently to be a
consequence of genetic polymorphisms at the level of
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Figure 5. Anti-proliferative effects of MTM analogs in ovarian cancer cells.
Ovarian cancer cells were incubated with increasing concentrations of MTM
(A),SK(B)andSDK(C).After72hcellsurvivalwasmeasuredbyMTTassay.
Data represent mean ± SD of triplicate samples. *P < 0.001 compared with
control cells.
Table 3. Effects of MTM and MTM analogs SK and SDK on growth of ovarian cancer cell lines
a
SKOV3 OVCAR3 OVCAR5 OVCAR432 OVCAR8 IGROV1 A2780
MTM (nM) 392.3 ± 100 184.8 ± 29 145 ± 73.8 83.7 ± 19.7 53.4 ± 15.4 136.2 ± 76.8 64.1 ± 9
SK (nM) 359.7 ± 67 215.6 ± 63.3 111.9 ± 50.6 80.2 ± 26.7 55.4 ± 18 147.3 ± 81.6 72.5 ± 20.4
SDK (nM) 182.5 ± 45.5 149.9 ± 46.4 108.4 ± 34.9 38.5 ± 7.1 26.6 ± 7.9 82.1 ± 49.2 28.9 ± 6.8
aMTTassayswereperformedafter72hofincubationofovariancancercelllineswithincreasingconcentrationsofthecompounds.Concentrationsthatinhibitedcell
growth by 50% (IC50) compared to control cells are reported. Data are mean ± SD of triplicate experiments.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1731Sp1-binding sites in the genes promoters (21,47,48). Because
of the large number of Sp1-regulated genes, abnormal Sp1
activity can contribute to various aspects of cancer, promoting
growth, survival, invasion, metastasis and angiogenesis. As
other transcription factors, Sp1 can be a valid therapeutic
target (1,2,42). Several strategies have been investigated to
inhibit Sp1 activity in experimental settings. Inhibition of Sp1
by decoy oligonucleotides and peptide nucleic acids,
small-interfering RNAs and ribozymes results in growth
inhibition and induction of apoptosis in various in vitro and
in vivo cancer models (49–51). Thus, GC-rich DNA-binding
compounds like SDK might represent valid agents for treat-
ment of cancers with aberrant Sp1 activity. The new MTM
analog was very effective in inhibiting growth and survival of
ovarian cancer cells that exhibited high levels of Sp1 protein
and binding activity. Even a short exposure to low doses
of SDK committed ovarian cancer cells to death and
growth arrest. Importantly, the potent anti-proliferative and
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1732 Nucleic Acids Research, 2006, Vol. 34, No. 6pro-apoptotic activity of SDK in cancer cells was not
associated with signiﬁcant cytotoxicity in normal cells. This
aspect is particularly relevant in light of the concerns
regarding selectivity and toxicity of DNA-binding agents
like SDK and will need to be further studied in appropriate
in vitro and in vivo animal models.
Abnormal Sp1 activity is involved also in diseases other
than cancer, including neurological and chronic degenerative
diseases (19,20,52–56). MTM has been investigated recently
as an experimental agent in neurological, hematological, car-
diovascular, chronic inﬂammatory and viral diseases (14–20).
MTM was found to protect cortical neurons from oxidative
stress-induced apoptosis (14) and to improve symptoms in a
Huntington’s disease mouse model (18). The drug’s activity in
these conditions could be attributed at least in part to its ability
to interact with GC-rich DNA sequences and interfere with
Sp1 or other DNA-binding proteins (14,16,19,20). New MTM
analogs, like SDK, should also be investigated in these disease
models, where they might exhibit improved activity and lower
toxicity compared to MTM.
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